Organization (Industry)
Pro Change Behavior Systems (United States)
ClinicalTrials.gov lists Pro Change Behavior Systems (United States) as lead sponsor of 16 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Pro Change Behavior Systems (United States): 16 lead-sponsored trials and 1 legal-entity registration.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Alzheimer Disease | 2 |
| Dementia | 2 |
| Substance-Related Disorders | 2 |
| Anxiety Disorders | 1 |
| Chronic Pain | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 0% on time (n=5) |
Journals published in (18)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Addiction (Abingdon, England) | 2 |
| American journal of health promotion : AJHP | 2 |
| Health psychology : official journal of the Division of Health Psychology, American Psychological Association | 2 |
| Adolescent medicine: state of the art reviews | 1 |
| Alcoholism treatment quarterly | 1 |
Showing 5 of 18 journals.
Financing and grant events (12)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-07-28 | SBIR award | 1,051,590 | Reporter |
| 2024-05-08 | SBIR award | 121,362 | Reporter |
| 2024-03-13 | SBIR award | 324,381 | Reporter |
| 2023-07-20 | SBIR award | 295,923 | Reporter |
| 2023-04-25 | SBIR award | 265,253 | Reporter |
Showing 5 of 12 events.
Latest dated events (31)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-08-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-28 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-06-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-05-08 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-04-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 31 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| OGN | Trial collaborator | Named in trial inclusion criteria |
| GAD2 | Trial sponsor | Exploratory endpoint in a trial |
| GAD2 | Trial sponsor | Mentioned in trial text |
| OGN | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.